A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

ClinicalTrials.gov ID

NCT07215559

Lead Sponsor

Eli Lilly and CompanyINDUSTRY

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

200Estimated

Last Update Posted

Sep 8, 2026Actual

Start Date

Oct 16, 2025Actual

Primary Completion Date

Mar 2027Estimated

Completion Date

May 2027Estimated

Official Title

A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes

Brief Summary

The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.

• Obesity
• Overweight
• Diabetes Mellitus, Type 2

• Macupatide
• Eloralintide
• Macupatide Placebo
• Eloralintide Placebo

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Have type 2 diabetes

• Have an HbA1c ≥7.5% to ≤10.5% at screening

• Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening

  • Diet and exercise
  • Stable dose of metformin
  • Sodium-glucose cotransporter-2 (SGLT2) inhibitor

• Have had a stable body weight (<5% body weight gain and/or loss) for the 3 months prior to screening

• Have a BMI of 27 or greater at screening

Exclusion Criteria:

• Have any form of diabetes other than type 2 diabetes

• Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening

• Have any of the following cardiovascular conditions within 3 months prior to screening:

  • acute myocardial infarction
  • cerebrovascular accident (stroke)
  • unstable angina, or
  • hospitalization due to congestive heart failure

• Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years, exceptions include

  • basal or squamous cell skin cancer
  • in situ carcinomas of the cervix, or
  • in situ prostate cancer

• Have been prescribed any of the following receptor agonists (RA) or their combination for any indication within the last 6 months:

  • amylin RA
  • dual amylin and calcitonin RA
  • glucagon-like peptide-1 receptor (GLP-1) RA
  • glucose-dependent insulinotropic peptide (GIP)/GLP-1 RA
  • GLP-1/glucagon (GCG) RAs, or
  • GIP/GLP-1/GCG RAs

• Have used excluded antihyperglycemic medications within 3 months prior to screening (including, but not limited to, sulfonylureas, dipeptidyl peptidase-4 inhibitors, alpha-glucosidase inhibitors, thiazolidinediones, and meglitinides

• Have used insulin for diabetic control within the prior year (short term use in certain situations allowed

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Double

Lead Sponsor

Eli Lilly and CompanyINDUSTRY

520329-4139

702-750-0000

609-392-6666

937-534-4201

281-944-3610

281-944-3610

713-973-3415

713-282-5600

5491128597742

5493364571637

61738765688

07 3397 3200

07 5408 0900

0395096166

7874842757

• A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

  NCT07589608

  RecruitingInterventionalPhase 2Updated Aug 6, 2026
• A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes

  NCT07765511

  Not yet recruitingInterventionalPhase 1Updated Aug 14, 2026
• A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

  NCT07282600

  RecruitingInterventionalPhase 3Updated Sep 8, 2026
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

  NCT07321886

  RecruitingInterventionalPhase 3Updated Aug 21, 2026
• A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

  NCT06230523

  CompletedInterventionalPhase 2Updated Jun 24, 2026
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  NCT07392190

  RecruitingInterventionalPhase 3Updated Sep 8, 2026